Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.
Aaron E. Katz, MD, FACS
Advertisement
Articles by Aaron E. Katz, MD, FACS
Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.
Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.
Aaron E. Katz, MD, FACS, discusses strategies for determining low-risk prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
The OncFive: Top Oncology Articles for the Week of 5/31
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5